Kalaris Therapeutics, Inc.
KLRS
We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor ( VEGF ) drug, specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with ex…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$43M
▲ +37.2% YoY
Op. Margin
–
ROIC
-57.35%
▼ -9.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$40M
▼ -86.6% YoY
Op. Cash Flow (TTM)
-$40M
▼ -85.6% YoY
Net Debt
-$82M
Net Cash Position
Cash & Equiv.
$83M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KLRS
Kalaris Therapeutics (KLRS) in three numbers
Questions about Kalaris Therapeutics
Is Kalaris Therapeutics a high-quality business?
Kalaris Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$82M, and its weakest is return on capital at -57.4%. The Quality tab shows every check against its target.
Does Kalaris Therapeutics (KLRS) pay a dividend?
No. Kalaris Therapeutics (KLRS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in KLRS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KLRS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.